Patients in England and Wales with cardiomyopathy caused by the disorder ATTR amyloidosis will soon be able to access treatment with Alnylam's gene-silencing drug Amvuttra. The ruling by reimbursement ...

TTR Stabilizers Gene Silencers Which Is Right for You? If youve been diagnosed with transthyretin cardiac amyloidosis (ATTR-CM), you may be debating between two treatments: transthyretin (TTR) ...

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a serious and debilitating heart condition that may require a collaborative team of experts. ATTR-CM not only affects the heart, it also often impacts ...

Alexandria Nyembwe is a registered nurse and health writer. She has worked in street medicine serving populations experiencing homelessness in Skid Row Los Angeles as well as in cardiovascular care in ...

First long-acting therapy with three-monthly dosing to target root cause of cardiac disease The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending ...

Fatigue is one of the most frustrating symptoms of transthyretin cardiac amyloidosis (ATTR-CM). It can reduce your overall quality of life, limiting your ability to complete daily tasks and ...

The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending vutrisiran for patients with wild-type and hereditary transthyretin amyloidosis with ...

ATTR-CM can be a life-changing diagnosis, and if you’re an older adult, it can have an especially large impact on your quality of life. Transthyretin amyloidosis cardiomyopathy (ATTR-CM) is a rare but ...

A promising new way to diagnose transthyretin amyloid cardiomyopathy (ATTR-CM or -CA) has the field waiting in anticipation. Early-phase research suggests that the positron emission tomography ...

The last time I spoke about Intellia Therapeutics (NTLA), it was with a Seeking Alpha article entitled "Nex-Z Advancement Remains On Track With Expanded ATTRv-PN Indication" With respect to this ...

Alnylam’s closely watched launch of its rare disease drug Amvuttra continued to outpace Wall Street expectations. Riding its March expansion into the heart condition of transthyretin amyloid ...